Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Palvella Therapeutics, Inc. on June 10, 2025. The meeting was conducted virtually. As of the record date of April 14, 2025, there were 11,042,965 outstanding shares of common stock entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the final voting results for three proposals submitted to stockholders:
- Proposal 1: Election of Class II Directors
- Elaine J. Heron, Ph.D.: Elected with 6,647,082 votes for, 1,255 votes withheld, and 667,256 broker non-votes.
- Tadd S. Wessel: Elected with 6,487,034 votes for, 161,303 votes withheld, and 667,256 broker non-votes.
- Both directors will serve until the 2028 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accountant
- Ernst & Young LLP was ratified for the 2025 fiscal year.
- Votes For: 7,299,907; Votes Against: 8,352; Abstentions: 7,334.
- Proposal 3: Advisory Approval of Executive Compensation (Say-on-Pay)
- Stockholders approved the 2024 compensation of named executive officers.
- Votes For: 6,550,393; Votes Against: 61,078; Abstentions: 36,866; Broker Non-Votes: 667,256.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the administrative outcomes of the annual shareholder meeting.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Elaine J. Heron and Tadd S. Wessel) extending to 2028.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2025 fiscal year.
- Note the significant number of broker non-votes (667,256) recorded for the director elections and the say-on-pay proposal, indicating shares held by brokers that were not voted on these specific matters.
- Review the definitive proxy statement filed on April 30, 2025, for detailed background on the proposals and director biographies.